50 was discovered as part of an alliance between Abbott and Enanta and is being developed with low-dose ritonavir, which enhances the pharmacokinetic properties of ABT-450, allowing for once-daily dosing. This Phase 2 study also evaluated ABT-333 and ABT-072, two of Abbott's internally discovered compounds that are part of the company's ongoing non-nucleoside polymerase inhibitor development program. The study findings for these two compounds have been submitted for presentation at a future scientific meeting.
About the Hepatitis C VirusHepatitis C is a liver disease affecting more than 180 million people worldwide. The virus is primarily spread through direct contact with the blood of an infected person. HCV increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death.
Liver disease associated with HCV infection is growing rapidly, and current therapies only cure about half of patients with the genotype 1 form of the virus. Specifically targeted antiviral therapies for HCV, such as protease inhibitors and non-nucleoside polymerase inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.
About Ritonavir The use of NORVIR® (ritonavir) with ABT-450 for the treatment of HCV is investigational.
NORVIR is in a class of medicines called the HIV protease (PRO-tee-ase) inhibitors. NORVIR is used in combination with other anti-HIV medicines to treat people with human immunodeficiency virus (HIV) infection. NORVIR is for adults and for children age greater than 1 month and older.
NORVIR does not cure HIV infection or AIDS and does not reduce the risk of passing HIV to others. People taking NORVIR may still get opportunistic infections or other conditions that happen with HIV infection. Some of these conditions are pneumonia, herpes virus infections, and Mycobacterium avium complex (MAC) infections.
People shouldPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine technology :1
. Abbott Again Recognized for Environmental Initiatives in Illinois2
. Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti3
. Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.4
. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia5
. Abbott Named One of the Top Employers in the Biotech and Pharmaceutical Industry by Science Magazine6
. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution7
. Abbotts XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial8
. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.9
. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results10
. The Deal Names Abbott Top Dealmaker for Third Consecutive Year11
. Abbott Declares 347th Consecutive Quarterly Dividend